VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology
Author(s) -
Gianni Cutillo,
David K. Simon,
Simona Eleuteri
Publication year - 2020
Publication title -
neurobiology of disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.205
H-Index - 166
eISSN - 1095-953X
pISSN - 0969-9961
DOI - 10.1016/j.nbd.2020.105056
Subject(s) - parkinson's disease , retromer , crosstalk , mitochondrion , mitophagy , lrrk2 , biology , parkin , microbiology and biotechnology , neuroscience , endosome , disease , genetics , intracellular , medicine , autophagy , apoptosis , pathology , physics , optics
Mutations in VPS35 (PARK17), a key molecule in the retromer complex, are a rare cause of autosomal dominant Parkinson's disease (PD), the second most common neurodegenerative disorder. VPS35 exerts crucial functions within the cell in terms of regulating endosomal trafficking. However new data suggest its relevance also in the regulation of mitochondrial dynamics and homeostasis. Herein, we review the crosstalk between VPS35 and the mitochondria, highlighting the potential relevance to PD pathogenesis. VPS35 is not only a critical player in pathways connected to α-synuclein accumulation and clearance, but also plays a key role in ensuring mitochondrial stability and function. The genetic links of VPS35 to PD and the involvement of VPS35 in different PD related pathological mechanisms highlight the potential for targeting VPS35 as a neuroprotective strategy for PD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom